Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer

HPB

Volumn 16, Issue 5, 2014, Pages 430-438

  Tzeng, Ching Wei D ^a   Balachandran, Aparna ^a   Ahmad, Mediha ^a   Lee, Jeffrey E ^a   Krishnan, Sunil ^a   Wang, Huamin ^a   Crane, Christopher H ^a   Wolff, Robert A ^a   Varadhachary, Gauri R ^a   Pisters, Peter W T ^a   Aloia, Thomas A ^a   Vauthey, Jean Nicolas ^a   Fleming, Jason B ^a   Katz, Matthew H G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; FLUOROURACIL; GEMCITABINE; TUMOR MARKER; BILIRUBIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS CANCER; PREDICTIVE VALUE; PREOPERATIVE PERIOD; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BLOOD; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PANCREAS RESECTION; PANCREATIC NEOPLASMS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; TIME; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; BILIRUBIN; CA-19-9 ANTIGEN; CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PANCREATECTOMY; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TEXAS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84899641764     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/hpb.12154     Document Type: Article

References (32)

1. Ballehaninna UK, Chamberlain RS,. (2012) The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence-based appraisal. J Gastrointest Oncol 3: 105-119.
2. Katz MH, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, Pisters PW, et al. (2010) Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol 17: 1794-1801.
3. Maithel SK, Maloney S, Winston C, Gonen M, D'Angelica MI, Dematteo RP, et al. (2008) Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol 15: 3512-3520.
4. Satoi S, Yanagimoto H, Toyokawa H, Inoue K, Wada K, Yamamoto T, et al. (2011) Selective use of staging laparoscopy based on carbohydrate antigen 19-9 level and tumour size in patients with radiographically defined potentially or borderline resectable pancreatic cancer. Pancreas 40: 426-432.
5. Sugiura T, Uesaka K, Kanemoto H, Mizuno T, Sasaki K, Furukawa H, et al. (2012) Serum CA 19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma. J Gastrointest Surg 16: 977-985.
6. Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, et al. (2012) The prognostic and predictive value of serum CA 19.9 in pancreatic cancer. Ann Oncol 23: 1713-1722.
7. Martin LK, Wei L, Trolli E, Bekaii-Saab T,. (2012) Elevated baseline CA 19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer. Med Oncol 29: 3101-3107.
8. Strobel O, Hartwig W, Hackert T, Hinz U, Berens V, Grenacher L, et al. (2013) Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival. Ann Surg Oncol 20: 964-972.
9. Bernhard J, Dietrich D, Glimelius B, Hess V, Bodoky G, Scheithauer W, et al. (2010) Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy. Br J Cancer 103: 1318-1324.
10. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC,. (2009) Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 16: 1727-1733.
11. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, et al. (2006) Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 13: 1035-1046. (Pubitemid 44337962)
12. Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, et al. (2008) Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206: 833-846; discussion 846-848.
13. National Comprehensive Cancer Network. (2012) Pancreatic adenocarcinoma Version 2.2012. NCCN Clinical Practice Guidelines in Oncology. Fort Washington, PA: NCCN.
14. Katz MH, Pisters PW, Lee JE, Fleming JB,. (2011) Borderline resectable pancreatic cancer: what have we learned and where do we go from here? Ann Surg Oncol 18: 608-610.
15. Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB, Casper ES, et al. (2012) Pancreatic adenocarcinoma, Version 2.2012 featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 10: 703-713.
16. Chatterjee D, Katz MH, Rashid A, Varadhachary GR, Wolff RA, Wang H, et al. (2012) Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer 118: 3182-3190.
17. Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, et al. (2012) Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 118: 5749-5756.
18. Tzeng CW, Fleming JB, Lee JE, Xiao L, Pisters PW, Vauthey JN, et al. (2012) Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol 19: 2045-2053.
19. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, et al. (2008) Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26: 3496-3502.
20. Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, et al. (2008) Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26: 3487-3495.
21. Hwang RF, Wang H, Lara A, Gomez H, Chang T, Sieffert N, et al. (2008) Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer. Ann Surg Oncol 15: 1356-1366.
22. Kang CM, Kim JY, Choi GH, Kim KS, Choi JS, Lee WJ, et al. (2007) The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res 140: 31-35. (Pubitemid 46669540)
23. Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, et al. (2009) Longterm survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 16: 836-847.
24. Tzeng CW, Abbott DE, Cantor SB, Fleming JB, Lee JE, Pisters PW, et al. (2013) Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. Ann Surg Oncol 20: 2197-2203.
25. Tzeng CW, Fleming JB, Lee JE, Wang X, Pisters PW, Vauthey JN, et al. (2012) Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB 14: 365-372.
26. Hartwig W, Strobel O, Hinz U, Fritz S, Hackert T, Roth C, et al. (2012) CA 19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol 20: 2188-2196.
27. Small W Jr, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF, et al. (2008) Full-dose gemcitabine with concurrent radiation therapy in patients with non-metastatic pancreatic cancer: a multicentre phase II trial. J Clin Oncol 26: 942-947. (Pubitemid 351398088)
28. Ohara K, Tatsuzaki H, Molotkova NG, Oda T, Yuzawa K, Saida Y, et al. (2001) Utility of serum CA 19-9 monitoring in preoperative radiotherapy for pancreatic cancer. Hepatogastroenterology 48: 859-863. (Pubitemid 32619699)
29. Willett CG, Daly WJ, Warshaw AL,. (1996) CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. Am J Surg 172: 350-352. (Pubitemid 26346949)
30. Park IJ, Choi GS, Lim KH, Kang BM, Jun SH,. (2009) Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level. Ann Surg Oncol 16: 3087-3093.
31. Park JW, Lim SB, Kim DY, Jung KH, Hong YS, Chang HJ, et al. (2009) Carcinoembryonic antigen as a predictor of pathologic response and a prognostic factor in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and surgery. Int J Radiat Oncol Biol Phys 74: 810-817.
32. Yakabe T, Nakafusa Y, Sumi K, Miyoshi A, Kitajima Y, Sato S, et al. (2010) Clinical significance of CEA and CA 19-9 in postoperative follow-up of colorectal cancer. Ann Surg Oncol 17: 2349-2356.